FDA’s newly proposed draft guidance will support IND filings of antisense oligonucleotides, a new class of drugs.
Following decades of research and study, a new class of drug, known as antisense oligonucleotides (ASO), are maturing as drug development efforts advance. In tandem with a growing ASO pipeline, FDA has recently issued a draft guidance, IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators, for dealing with ASO investigational new drug filings.
BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 6–10
When referring to this article, please cite it as F. Mirasol, “Growing Pipeline of Antisense Oligonucleotides Prompts Guidance," BioPharm International Regulatory Sourcebook eBook (March 2021).
over 5 years ago
It Takes a Bio/Pharma Villageover 5 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 5 years ago
Can FDA Reinvent Inspections?over 5 years ago
Gene Therapies Target Neurodegenerative Diseasesover 5 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 5 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 5 years ago
Regulatory and Standard Setting Organizations Directory
